Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Oct;48(10):4009-11.
doi: 10.1128/AAC.48.10.4009-4011.2004.

Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs

Javier Capilla  1 , Josep Guarro
Affiliations

Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs

Javier Capilla et al. Antimicrob Agents Chemother. 2004 Oct.

Abstract

We have evaluated the efficacy of voriconazole (VRC) in a systemic infection by Scedosporium apiospermum in immunodepressed guinea pigs. Animals were infected with two strains; one required a VRC MIC of 0.5 to 1 microg/ml, common for this fungus, and the other required a high MIC (8 microg/ml), unusual in this species. VRC prolonged survival and reduced fungal load in kidney and brain tissues of the animals infected with the first strain but was unable to prolong survival or to reduce fungal load in brain tissue for the latter strain.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Survival of Hartley immunodepressed guinea pigs infected with S. apiospermum (FMR 6694) at concentration of 7 × 105 CFU/animal. Animals were treated for 10 days with VRC p.o. at 5 (▾), 10 (•) or 20 (▴) mg/kg/day or AMB i.p. at 1.5 mg/kg/day (▪).
FIG. 2.
FIG. 2.
Survival of Hartley immunodepressed guinea pigs infected with S. apiospermum (FMR 6922) at a concentration of 3 × 105 CFU/animal. Animals were treated for 10 days with VRC p.o. at 10 (•) or 20 (▴) mg/kg/day or AMB i.p. at 1.5 mg/kg/day (▪).
See this image and copyright information in PMC

References

    1. Capilla, J., C. Serena, F. J. Pastor, M. Ortoneda, and J. Guarro. 2003. Efficacy of voriconazole in treatment of systemic scedosporiosis in neutropenic mice. Antimicrob. Agents Chemother. 47:3976-3978. - PMC - PubMed
    1. Carrillo, A. J., and J. Guarro. 2001. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother. 45:2151-2153. - PMC - PubMed
    1. Castiglioni, B., D. A. Sutton, D. M. G. Rinaldi, J. Fung, and S. Kusne. 2002. Pseudallescheria boydii (anamorph Scedosporium apiospermum) infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine 81:333-348. - PubMed
    1. Chandrasekar, P. H., J. Cutright, and E. Manavathu. 2000. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J. Antimicrob. Chemother. 45:673-676. - PubMed
    1. Cuenca-Estrella, M., B. Ruiz-Diez, J. V. Martínez-Suárez, A. Monzón, and J. L. Rodríguez-Tudela. 1998. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J. Antimicrob. Chemother. 43:149-151. - PubMed

MeSH terms

LinkOut - more resources